The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: A review of the literature

Pediatric Hematology and Oncology

Volumn 25, Issue 7, 2008, Pages 655-664

  Mavinkurve Groothuis, Annelies M C ^a,c   Kapusta, Livia ^a   Nir, Amiram ^b   Groot Loonen, Jacqueline ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c Dept of Pediatric Hemato oncology ^*  (Netherlands)

Author keywords

Anthracycline induced cardiotoxicity; Biomarkers; Natriuretic peptides; Troponins

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; TROPONIN I; TROPONIN T;

ADOLESCENT; ARTICLE; CARDIOTOXICITY; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; NON INVASIVE MEASUREMENT; PROTEIN BLOOD LEVEL;

ANTHRACYCLINES; BIOLOGICAL MARKERS; CHILD; EARLY DIAGNOSIS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; PEPTIDE FRAGMENTS; TROPONIN I; TROPONIN T;

EID: 53749090347     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010802244001     Document Type: Article

References (47)

1. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group Experience. J Clin Oncol. 1997;15:1544-1552.
2. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-153.
3. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994;93:433-437.
4. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies Br J Haematol. 2005;131:561-578.
5. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197-1202.
6. Meinardi MT, Van Der Graaf WTA, van Veldhuisen DJ, Gietema JA, de Vries EGE, Sleijfer DTh. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237-247.
7. Kapusta L, Thijssen JM, Groot-Loonen J, van Druten JA, Daniels O. Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines. Ultrasound Med Biol. 2001;27:1605-1614.
8. Kapusta L, Groot-loonen J, Thijssen JM, de Graaf R, Daniels O. Regional cardiac wall motion abnormalities during and shortly after anthracycline therapy. Med Pediatr Oncol. 2003;41:426-435.
9. Weidemann F, Eyskens B, Sutherland GR. New ultrasoundmethods to quantify regional myocardial function in children with heart disease. Pediatr Cardiol. 2002;23:292-306.
10. Voigt JU, Flachskampf FA. Strain and strain rate: new and clinically relevant echo parameters of regional myocardial function. Z Kardiol. 2004;93:249-258.
11. Horecek JM, Pudul R, Tichy M, et al. The use of biomarkers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52:430-434.
12. Sparano JA, Wolff AC, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. Lancet. 2000;356:1947-1948.
13. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002;25:301-311.
14. Collinson PO, Stubbs PJ. Are troponins confusing? Heart. 2003;89:1285-1287.
15. Parsonage WA, Galbraith AJ, Koerbin GL, Potter JM. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for esthablished chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;95:883-885.
16. Doust JA, Pietrzak E, Dobson A, Glasziou PP. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.
17. Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation. 2003;108:2368-2376.
18. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail. 2005;(5 Suppl):S76-S80.
19. Immer FF, Stocker FP, Seiler AM, Pfammatter JP, Printzen G, Carrel TP. Comparison of troponin-I and troponin-T after pediatric cardiovascular operation. Ann Thorac Surg. 1998;66:2073-2077.
20. Swaanenburg JC, Klaase JM, de Jongste MJ, Zimmerman KW, ten Duis HJ. Troponin I, troponin T, CKMB-activity and CKMB-mass as markers for the detection of myocardial contusion in patients who experienced blunt trauma. Clin Chim Acta. 1998;272:171-181.
21. Clarks SJ, Newland P, Thorburn K. Troponin I versus troponin T: is there actually a debate in children with sepsis? Crit Care Med. 2001;29:1093-1094.
22. Soldin SJ, Murthy JN, Agarwalla PK, Ojeifo O, Chea J. Pediatric reference ranges for creatine kinase, CKMB, Troponin I, iron, and cortisol. Clin Biochem. 1999;32:77-80.
23. Hirsch R, Landt Y, Porter S, et al. Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury. J Pediatr. 1997;130:872-877.
24. Schwachtgen L, Herrmann M, Georg G, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol. 2005;94:399-404.
25. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82:218-222.
26. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose. J Am Coll Cardiol. 2000;36:517-522.
27. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136:362-363.
28. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104:158-163.
29. Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145:212-220.
30. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Med Pediatr Oncol. 2001;37:4-9.
31. Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Uluoglu O, Akyurek N. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005;44:370-377.
32. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349-2356.
33. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T. B-Type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer. 2006;Dec 14.
34. Erkus B, Demirtas S, Yarpuzlu AA, Can M. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 2007;96:506-509.
35. Ekstein S, Nir A, Perles Z, Rein AJJT, Weintraub M. NT-pro-BNP as a potential marker for acute anthracycline cardiotoxicity in children. Cardiol Young. 2005;15(Suppl 2):75.
36. Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol. 2006;108:212-215.
37. Kremer LC, Bastiaansen BAJ, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer. 2002;38:686-689.
38. Fink M, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol. 1995;25:185-189.
39. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641-2648.
40. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer. 2004;42:220-224.
41. Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest. 2001;19:352-359.
42. Koseoglu V, Berberoglu S, Karademir S, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? Turk J Pediatr. 2005;47:17-22.
43. Landier W, Bhatia S, Eshelman DA, et al. Developmant of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;2:4979-4990.
44. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
45. Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur.J Cancer. 2007;43:1959-1966.
46. Richards AM, Cohn JN. N-terminal pro-brain natriuretic peptide: a powerful biomarker of cardiac disease. J Card Fail. 2005;11(Suppl):1-2.
47. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002;110:e76.